Investing.com -- Fever-Tree Drinks on Thursday reported full-year 2025 sales of £375.3 million, slightly ahead of analyst expectations of £373.2 million, with organic sales growth of 3%.
The premium mixer company showed improving trends in the second half of the year, particularly in the US where the transition into TAP’s 400-strong distributor network has been successful with 6% underlying growth.
The UK market demonstrated a clear second-half inflection, moving from mid-single digit declines in the first half to approximately flat performance in the second half. This improvement was driven by off-trade resilience and faster growth in non-tonic products.
In other regions, France remained a standout performer while Benelux showed improvement, though Germany continues to face challenges. Rest of World growth was strong with some favorable shipment phasing, but underlying second-half growth still reached double digits.
Following the completion of a £100 million share buyback program in 2025, Fever-Tree will begin an additional £30 million buyback in February, reflecting confidence in the company’s cash generation capabilities.
The company is expected to report its full profit and loss statement on March 24. Analysts maintain a price target of £11.00 for the stock, representing a 24% upside from the current price of 890.00p.
Looking ahead to 2026, Fever-Tree is positioned to benefit from its TAP partnership, which is expected to provide increased scale and execution capability in the US market, along with enhanced marketing support to boost brand awareness.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.






















